implants - international magazine of oral implantology International Edition

I manufacturer news 36 I implants1_2014 Implant systems are normally tested according to the DIN EN ISO 14801 Norm before they are launched. LARADO presents an especially developed dental im- planttestingunit—DORA14801—whichguarantees theobservanceandconsistencyforproductqualitybe- fore and during production and also allows for imme- diate design modifications. The DIN EN ISO 14801 Normconcernsitselfwiththetestingofdentalimplants regarding wear and failures caused by alternating stressorloads.TheDORA14801providesasimpleand economicsolutionfortestingwithamaximumofeffi- ciency regarding cost and time.In principle; it relates to the quality of implants which must be insured not only in the development phase, but also in later pro- duction by batch and ISO 14801-exams.Thus,a high levelofsecurityisobtainedwithrespecttoendurance, connectionandstructureofimplants.Themainfactor of efficiency is obtained through one master control unit and is the basis for the connection of 1 to 8 indi- vidual test stations that provides independent, vali- dated and documented test results. A variable sinus amplitudeanddynamic-powerofupto800Natavari- ableof1–15Hz,alow-spacerequirementformachine placement, the simple connection to a 110–230-volt power-outletandtheindependencefromcompressed airorhydraulicsystemsaresomeoftheadvantagesof theDORA14801. LARADO Mainzer Str. 346 55411 Bingen am Rhein, Germany www.14801.de In2014theStraumann® DentalImplantSystemoffers morevaluefordentalcliniciansandpatients.Ourprod- uct range focuses on the groundbreaking Roxolid® material,which is specifically designed for the use in dental implantology. Outstanding biological and me- chanical properties allow Roxolid® Implants to offer more treatment options than conventional titanium implants. Moretreatmentoptionswithsmallerimplants:there- duced-diameter Roxolid® Implants with the hy- drophilicSLActive® surfaceandhigherstrengthrevo- lutionizedthemarketin2009.AttheEAO2013Strau- mann launched a new range of sizes of Roxolid® SL- Active® Implantsaswellasa4mmRoxolid® SLActive® Implant.This Roxolid® SLActive® Short Implant is de- signed to avoid extensive bone augmentation proce- dures.Now,in2014forthefirsttime,Roxolid® Implants arealsoavailablewiththewell-establishedSLA® sur- face.Roxolid® –settingnewstandards,reducinginva- siveness:offeringallimplantswiththeRoxolid® mate- rial helps dental professionals to reduce the invasive- ness of implant treatments by using smaller, shorter implants which are stronger than conventional tita- niumimplants.Roxolid® helpstoavoidpatienttrauma, pain and discomfort while saving time and money. Straumann® Roxolid® Implants are delivered with the newLoxim™TransferPiece,whichisconnectedtothe implant with a snap-in mounting and offers clinicians manybenefits.Straumann–simplydoingmore. Institut Straumann AG Peter Merian-Weg 12 4052 Basel, Switzerland www.straumann.com Straumann More than an implant. A sense of trust. LARADO Implant test unit allows testing during production Nobel Biocare launches its latest innovation, creos xeno.protect,beginningintheEuropeanmarkets.This new collagen membrane will be part of a larger re- generative product line under the brand name “creos”. Additional products will follow this year. “The introduction of creos xeno.protect emphasises Nobel Biocare’s long-standing commitment to im- proving quality of life through innovation.It is a prod- uctthatharnessestheingenuityofnaturetotheben- efit of the patient,while at the same time making life easier for the clinician,” said Nobel Biocare CEO, RichardLaube. Clinical studies and early results from clinicians after an extensive prelaunch period confirm it possesses optimalhandlingqualities,maintainsitssizewhenhy- drated and is very tear-resistant.1 The optimal fit can be found without extensive trimming which limits wasteandminimizescostsforbothcliniciansandpa- tients.The creos xeno.protect membrane has an ex- tended barrier function that does not compromise on the established high industry standards for biocom- patibilityorvascularizationbehavior.Asitisproduced withoutanychemicalcrosslinking,creosxeno.protect offershightissuecompatibilityforfastandpredictable healing. 1 Clinicalstudies,productinformationandfirst-userfeedbackareavailableatcreos.com/xeno- protect. Nobel Biocare PO Box 8058 Zurich Airport, Switzerland www.nobelbiocare.com Nobel Biocare Entering the regenerative field Manufacturer News